IR BioSciences Holdings, Inc. Announces a 2-for-1 Forward Stock Split

IR BioSciences Holdings, Inc. Announces a 2-for-1 Forward Stock
Split 


SCOTTSDALE, Ariz., April 6  /PRNewswire-FirstCall/ -- IR Biosciences Holdings,
Inc.  (BULLETIN BOARD: IRBO)  (formerly OTC Bulletin Board: IRBH) today
announcedthat its Board of Directors approved a two-for-one forward stock split
of its common stock.  Each share of the Company's common stock held by each
stockholder of record at the close of business on April 5, 2004 (record date)
will be reclassified and subdivided into two shares of the Company's common
stock.  Each stockholder of record at the close of business on the record date
may turn in their stock certificates to the transfer agent for new stock
certificates.

In connection with the forward stock split, the Company's trading symbol changed
from "IRBH" to "IRBO" effective at the opening of the markets on April 6, 2004. 
The stock will continue to trade on the OTC Bulletin Board.

About IR BioSciences Holdings, Inc.

IR BioSciences Holdings, Inc.,formed in 2003, is the sole owner of ImmuneRegen
BioSciences, Inc., a biotechnology company engaged in the research and
development of applications utilizing modified Substance P, a naturally
occurring immunomodulator.  Derived from homeostatic substance P, ImmuneRegen
has named their proprietary compound "Homspera."  IR BioSciences Holdings,
Inc.'s initial focus is on the continuing development of Homspera for various
applications for use in improving pulmonary function and stimulating the human
immune system.  For more information, please visit the company's website at
http://www.immuneregen.com/.

The matters discussed in this news release contain forward looking statements
including relating to the plans of IR BioSciences Holdings, Inc. to effect a
two-for-one forward stock split and the timing thereof that are subject to
certain risks and uncertainties.  IRBH assumes no obligation to update the
information in this release. 

DATASOURCE: IR BioSciences Holdings, Inc.



CONTACT:  media, Michelle Derden of Spelling Communications,

[phone], ; or investors, Tony Schor of

InvestorAwareness, [phone], , both for IR

BioSciences Holdings, Inc.



Web site:  http://www.immuneregen.com/ 

Copyright